Natural History and Functional Status Study of Patients With Lafora Disease

Ionis Pharmaceuticals, Inc.33 enrolled

Overview

A natural history and functional status study to characterize the clinical disease course in Lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future Lafora treatment studies.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lafora Disease

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Documented genetic diagnosis of Lafora disease based on mutations in both alleles of either the EPM2A or the EPM2B gene and a sibling with a known mutation in EPM2A or EPM2B. 2. Able and willing to comply with the study protocol, including travel to Study Center, procedures, measurements and visits, including: 1. Adequately supportive psychosocial circumstances, in the opinion of the Investigator 2. Caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age. 3. Adequate visual and auditory acuity for neuropsychological testing Exclusion Criteria: 1. Any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype 2. Subjects with: 1. complete absence of speech OR 2. inability to perform any activities of daily living OR 3. who are completely bedridden. 3. Current participation in an interventional or therapeutic study 4. Receiving an investigational drug within 90 days of the Baseline Visit 5. Prior or current treatment with gene or stem cell therapy 6. Any other diseases which may significantly interfere with the assessment of Lafora disease. 7. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study.

Locations (4)

IONIS Investigative Site

Los Angeles, California, United States

IONIS Investigative Site

Dallas, Texas, United States

IONIS Investigative Site

Bologna, Italy

IONIS Investigative Site

Madrid, Spain

Outcomes

Primary Outcomes

Changes over time in symptom-directed physical exams, measured by height assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by weight assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by head, eyes, ears, nose, and throat assessment (HEENT)

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by cardiovascular assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by musculoskeletal assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by respiratory assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by abdomen assessment

Time frame: 24 Months

Changes over time in symptom-directed physical exams, measured by skin findings

Time frame: 24 Months

Changes in disease-related symptoms over time assessed by the Lafora Disease Performance Scale

Time frame: 24 Months

Seizure frequency, (by type and severity) as recorded in seizure diary

Time frame: 24 Months

Seizure duration, as measured by awake video EEG

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.